Homewood, AL, United States of America

Ping Chen

This inventor holds 3 USPTO granted patents. Top assignee: The UAB Research Foundation (The University of Alabama at Birmingham). Active years: 2002-2010.


% Patents Active = 66.7

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2002-2010

Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Ping Chen

Introduction

Ping Chen is an accomplished inventor based in Homewood, AL (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibiotic compositions. With a total of 3 patents to his name, Chen's work has the potential to impact medical science and antibiotic treatments.

Latest Patents

Among his latest patents is a groundbreaking invention related to lanthionine antibiotic compositions and methods. This patent discloses an isolated and purified DNA sequence that encodes a lantibiotic known as mutacin I. The nucleic acid sequence is detailed in SEQ ID No: 1, while the amino acid sequence is provided in SEQ ID No: 2. Another notable patent by Chen focuses on mutacin I biosynthesis genes and proteins, further emphasizing the importance of this lantibiotic in medical applications.

Career Highlights

Ping Chen is affiliated with the UAB Research Foundation, which is part of the University of Alabama at Birmingham. His work at this esteemed institution has allowed him to explore innovative solutions in antibiotic research.

Collaborations

Chen has collaborated with notable colleagues, including Fengxia Qi and Page W Caufield, enhancing the scope and impact of his research endeavors.

Conclusion

Ping Chen's contributions to antibiotic research through his patents and collaborations highlight his role as a significant inventor in the field. His work continues to pave the way for advancements in medical science and antibiotic treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…